Hikma Pharmaceuticals PLC (HIK.L) Stock Price
£1632 1.7%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
8 -
Technical
2
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals. Scores are designed to reflect relative strength or weakness across these factors, helping users compare companies and track changes over time.
Sign up to get access to more historical data and insights on Hikma Pharmaceuticals PLC, AI stock picks, stock alerts and much more.
HIK.L AI Stock Analysis
AI stock analysis for HIK.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Hikma Pharmaceuticals PLC (HIK.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Hikma Pharmaceuticals PLC (HIK.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Hikma Pharmaceuticals PLC (HIK.L), currently trading at £1632, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About HIK.L
-
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.
-
Symbol
HIK.L
-
Market
LSE
-
Industry
Drug Manufacturers - Specialty & Generic
-
Market Cap
3.6B
Similar Stocks
 |
Shield Therapeutics STX.L |
£9 9.8% |
5 |
 |
Haleon plc HLN.L |
£361.9 0.6% |
7 |
 |
HUTCHMED (China) Limited HCM.L |
£260 8.8% |
6 |
 |
ECO Animal Health Group EAH.L |
£73.5 0.00% |
7 |
 |
Venture Life Group VLG.L |
£58 1.7% |
5 |
News
HIK.L Alternative Data
Web Traffic
Hikma Pharmaceuticals PLC receives an estimated 153853 monthly visitors to hikma.com, which is down by -10% over the last month.
-
Web Traffic
153853
-
Change from Previous Month
10%
-
3 Month Change
1.7%
-
YoY Change
1.7%
Twitter Followers
Hikma Pharmaceuticals PLC has 2,912 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.2% over the last month.
-
Twitter Followers
2912
-
Daily Change
0%
-
1 Month Change
0.2%
-
3 Month Change
0.8%
-
YoY Change
0.8%
Facebook Engagement
Hikma Pharmaceuticals PLC has engaged 485 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
485
-
Daily Change
1.3%
-
1 Month Change
6.8%
-
3 Month Change
36.2%
-
YoY Change
36.2%
Instagram Followers
Hikma Pharmaceuticals PLC has 17,430 Instagram Followers on its main Instagram account, up by 1.6% over the last month.
-
Instagram Followers
17430
-
Daily Change
0%
-
1 Month Change
1.6%
-
3 Month Change
3.9%
-
YoY Change
3.9%
Youtube Subscribers
Hikma Pharmaceuticals PLC has 12,800 subscribers on its main Youtube channel.
-
Youtube Subscribers
12800
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0.8%
-
YoY Change
0.8%
Job Postings
Hikma Pharmaceuticals PLC currenly has an estimated 88 open job postings, up by 20.5% over the last month.
-
Job Postings
88
-
Daily Change
4.3%
-
1 Month Change
20.5%
-
3 Month Change
4.3%
-
YoY Change
4.3%
Reddit Mentions
Hikma Pharmaceuticals PLC has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Followers
587,617 are following Hikma Pharmaceuticals PLC on LinkedIn, up by 2.6% over the last month.
-
LinkedIn Followers
587617
-
Daily Change
2.6%
-
1 Month Change
2.6%
-
3 Month Change
6.3%
-
YoY Change
6.3%
Business Outlook
According to employee reviews, the business outlook among employees at Hikma Pharmaceuticals PLC is 57 out of 100 (neutral), down by -1.7% over the last month.
-
Business Outlook
57
-
Change from Previous Month
1.7%
-
3 Month Change
1.7%
-
YoY Change
1.7%
LinkedIn Employees
According to LinkedIn, Hikma Pharmaceuticals PLC has 9,947 employees, up by 1.1% over the last month.
-
LinkedIn Employees
9947
-
Daily Change
1.1%
-
1 Month Change
1.1%
-
3 Month Change
2.5%
-
YoY Change
2.5%
News Mentions
Hikma Pharmaceuticals PLC was mentioned 1 times in the news yesterday.
-
News Mentions
1
-
Daily Change
50%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
HIK.L Financials
HIK.L Key Metrics
-
Total Revenue
$1.6B
-
Net Income
$133M
-
Earnings per Share
$0.6
-
Free cash flow
$270M
-
EBITDA
$288M
-
EBITDA Ratio
0.184852
-
Total Assets
$5.1B
HIK.L 2-year Revenue & Income
HIK.L 2-year Free Cash Flow
HIK.L Technicals
HIK.L SMA
HIK.L RSI
FAQ
What's the current price of Hikma Pharmaceuticals PLC (HIK.L) Stock?
The price of an Hikma Pharmaceuticals PLC (HIK.L) share is £1632.
What's the market cap of Hikma Pharmaceuticals PLC?
The current market cap of Hikma Pharmaceuticals PLC is 3.6B.
Should I buy or sell HIK.L?
Hikma Pharmaceuticals PLC shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Hikma Pharmaceuticals PLC is better viewed as a hold or accumulate position while waiting for further developments.
Is Hikma Pharmaceuticals PLC a good investment?
The current analysis of Hikma Pharmaceuticals PLC's fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Hikma Pharmaceuticals PLC's portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Hikma Pharmaceuticals PLC (HIK.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Hikma Pharmaceuticals PLC stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Hikma Pharmaceuticals PLC (HIK.L) that investors often compare it to?
Hikma Pharmaceuticals PLC (HIK.L) is often compared to similar stocks such as Shield Therapeutics, Haleon plc, HUTCHMED (China) Limited, ECO Animal Health Group and Venture Life Group.
What is the forecast for Hikma Pharmaceuticals PLC's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Hikma Pharmaceuticals PLC's stock price to be around £1678.8 in 2026. Starting from the current price of £1632, this represents a 2.9% change in price, indicating a neutral outlook for the stock.
How to buy Hikma Pharmaceuticals PLC (HIK.L) Stock?
Hikma Pharmaceuticals PLC stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Hikma Pharmaceuticals PLC shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.